IL-36 beta/IL-1F8 Antibody [Unconjugated]

Recombinant Human IL-36 beta / IL-1F8 (aa 5-157) (Catalog # 6834-IL) induces IL-8 secretion in human pre-adipocytes in a dose-dependent manner (orange line). IL-8 Secretion elicited by Recombinant Human IL-36 beta / IL-1F8 (aa 5-157) (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-36 beta /IL-1F8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1099). The ND50 is typically 50-300 ng/mL.

• Reactivity: Hu
• Applications: B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-36 beta/IL-1F8 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human IL‑36 beta /IL‑1F8
  Met1-Glu157
  Accession # Q3MIH0
• Specificity: Detects human IL-36 beta /IL-1F8 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) IL-36 gamma and rhIL-36 alpha is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL36B
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction 100 ug/mL
  • Neutralization 50-300 ng/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-36 beta/IL-1F8 Antibody [Unconjugated]

• family of interleukin 1-eta
• FIL1 eta
• FIL1
• FIL1-(ETA)
• FIL1H
• FILI-(ETA)
• IL-1 eta
• IL1-ETA
• IL1F8 (Canonical product IL-1F8a)
• IL-1F8 (FIL1-eta)
• IL1F8
• IL-1F8
• IL1H2
• IL-1H2
• IL36 beta
• IL-36 beta
• IL36B
• interleukin 1 family, member 8 (eta)
• interleukin 1, eta
• Interleukin 36, Beta
• Interleukin-1 eta
• interleukin-1 family member 8
• Interleukin-1 homolog 2
• Interleukin-1 Superfamily e
• Interleukin-36 Beta

Background

Human interleukin 1 family member #8 [IL-1F8; also named Interleukin-36 beta, IL36B, FIL-1 eta (eta) and IL-1H2] is a member of the IL-1 family of proteins (1-3). IL-1 family members include IL-1 beta , IL-1 alpha , IL-1ra, IL-18 and IL-1F5 through F10 (4). All family members show a 12 beta -stranded beta -trefoil configuration, and are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid (aa) residues have been reported (3). IL-1F8 isoform 2 is synthesized as a 157 aa protein that contains no signal sequence and no prosegment (1, 2). Unlike IL-1F8 isoform 1 which lacks potential N-linked glycosylation sites, isoform 2 contains one potential N-linked glycosylation site in its unique C-terminus. IL-1F8 is reported to be actively secreted (1). Human IL-1F8 isoform 2 shares 61% aa identity with mouse IL-1 ra, a 183 aa form of IL-1F8. Within the IL-1 family, IL-1F8 shares 30%, 32%, 37%, 46%, 34%, 45% and 28% aa sequence identity with IL-1 ra, IL-1 beta , IL-1F5, F6, F7, F9 and F10, respectively. Cells reported to express IL-1F8 include resting and activated monocytes and B cells (1, 4). The receptor for IL-1F8 is reported to be a combination of IL-1 Rrp2 and IL-1 RAcP (5). Recombinant IL-1F8, along with IL-1F6 and IL-1F9, has been shown to activate the pathway involving NF-kappa B and MAPK in an IL-1 Rrp2 dependent manner.

1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
2. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
3. Nicklin, M.J.H. et al. (2002) Genomics 79:718.
4. Dunn, E. et al. (2001) Trends Immunol. 22:533.
5. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-36 beta/IL-1F8 Antibody (AF1099)(4)

Publications using AF1099

• Zhan, ZY;Zhang, ZH;Sun, RH;Wu, YL;Nan, JX;Lian, LH; A therapeutic strategy of parthenolide in improving imiquimod-induced psoriasis-like skin inflammation targeting IL-36/NETs through skin transdermal therapeutic system International immunopharmacology 2024-03-09 [PMID: 38461633] (Western Blot, Human)
• JM Murrieta-C, RN Gutiérrez-, HM El-Shorafa, T Groten, S Rodríguez-, ME Cancino-Di, JC Cancino-Di, RR Favaro, UR Markert, DM Morales-Pr Role of IL-36 Cytokines in the Regulation of Angiogenesis Potential of Trophoblast Cells International Journal of Molecular Sciences, 2020-12-30;22(1):. 2020-12-30 [PMID: 33396613] (Western Blot, Human)
• Lian LH, Milora KA, Manupipatpong KK, Jensen LE The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36 gamma. J. Invest. Dermatol., 2012-02-09;132(5):1346-53. 2012-02-09 [PMID: 22318382] (Western Blot, Human)
• Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, Bas S, Duffy T, Noger M, Guerne PA, Nicklin MJ, Gabay C The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res. Ther., 2006-04-28;8(3):R80. 2006-04-28 [PMID: 16646978] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: IL36B
• Uniprot:
  • Q3MIH0()